Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | CDC25A | P30304 | 1/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29999179 | 0.88 | TLR7 (0.61) | ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL20988524 | 0.86 | TLR7 (0.63) | ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14481411 | 0.86 | TLR7 (0.63) | ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL20988339 | 0.86 | TLR7 (0.60) | ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL24247810 | 0.85 | TLR7 (0.58) | ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9823724 | 0.84 | ALDH1A1 (0.63) | ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL20646867 | 0.84 | TLR7 (0.57) | ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29660311 | 0.84 | ALDH1A1 (0.64) | ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL25003939 | 0.82 | TLR7 (0.66) | ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5342437 | 0.82 | ALDH1A1 (0.65) | ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848545-B | 1- (2- (4-methoxyphenyl) thiazole-4-yl) ethylamine and synthetic method thereof | 南通大学 | 2022-08-12 | — | — | CN | claimed |
| CN-111848545-A | 1- (2- (4-methoxyphenyl) thiazole-4-yl) ethylamine and synthetic method thereof | 南通大学 | 2020-10-30 | — | — | CN | claimed |
| US-20260062407-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4577211-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | Wake Forest University Health Sciences (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2025-01-09 | — | — | US | disclosed |
| WO-2024044744-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044744-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023170024-A1 | CAMK2 MODULATORS AND THEIR USE IN MEDICINE | UNIVERSITY OF COPENHAGEN (DK) | 2023-09-14 | — | — | WO | disclosed |
| CN-111848545-B | 1- (2- (4-methoxyphenyl) thiazole-4-yl) ethylamine and synthetic method thereof | 南通大学 | 2022-08-12 | — | — | CN | disclosed |
| CN-111848545-A | 1- (2- (4-methoxyphenyl) thiazole-4-yl) ethylamine and synthetic method thereof | 南通大学 | 2020-10-30 | — | — | CN | disclosed |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| US-9206142-B2 | Anilinopiperazine derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20120328691-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2012-12-27 | — | — | US | disclosed |
| CN-101370796-B | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE | 2012-10-10 | — | — | CN | disclosed |
| EP-2078003-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008054702-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-0262873-B1 | N-TETRAZOLYL THIAZOLECARBOXAMIDE DERIVATIVES AND THEIR USE | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1991-08-21 | — | — | EP | disclosed |
| US-4879295-A | ANTIALLERGENS | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1989-11-07 | — | — | US | disclosed |
| EP-0262873-A1 | N-tetrazolyl thiazolecarboxamide derivatives and their use | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1988-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062407-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX3, PRDX2 | ALDH1A1 748/4885KDM4E 3228/4885RAB9A 1459/4885 |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | MALT1, APC, UACA | ALDH1A1 1447/4885KDM4E 1366/4885RAB9A 4531/4885 |
| US-20120328691-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MAPK15, CDK15, MAPKAPK5 | ALDH1A1 3548/4885KDM4E 3595/4885RAB9A 4564/4885 |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | ALDH1A1 331/4885KDM4E 2664/4885RAB9A 2759/4885 |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | ALDH1A1 319/4885KDM4E 2634/4885RAB9A 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.